Forte Biosciences Inc Ordinary Shares FBRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FBRX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.52
- Day Range
- $0.50–0.51
- 52-Week Range
- $0.38–1.03
- Bid/Ask
- $0.50 / $0.51
- Market Cap
- $18.59 Mil
- Volume/Avg
- 2,075 / 22,452
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.fortebiorx.com
Valuation
|
Metric
|
FBRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.65 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
FBRX
Financial Strength
|
Metric
|
FBRX
|
|---|---|
Quick Ratio | 9.14 |
Current Ratio | 9.45 |
Interest Coverage | — |
Quick Ratio
FBRX
Profitability
|
Metric
|
FBRX
|
|---|---|
Return on Assets (Normalized) | −77.45% |
Return on Equity (Normalized) | −89.16% |
Return on Invested Capital (Normalized) | −89.16% |
Return on Assets
FBRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Yjxltjfzwy | Rwyl | $620.9 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zswpdmz | Lmssn | $121.4 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jbvrlrrpm | Nlxrjwt | $112.8 Bil | |||
| Moderna Inc
MRNA
| Lqtqkkz | Jlf | $44.4 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mpvqrdlc | Vqjjsc | $31.5 Bil | |||
| argenx SE ADR
ARGX
| Ytbpzkjyn | Rdvh | $25.8 Bil | |||
| BioNTech SE ADR
BNTX
| Hcqjvmn | Ppfq | $19.2 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pdzkhjfp | Prdbffq | $15.4 Bil | |||
| United Therapeutics Corp
UTHR
| Fykjzbrv | Zyzr | $13.8 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Qqsfnmdls | Nrjvsv | $11.7 Bil |